These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 16326100

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
    Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A, Serum HER-2/neu Study Group.
    Cancer; 2008 Sep 15; 113(6):1294-301. PubMed ID: 18661530
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G, Köstler WJ, Czerwenka K, Kubista E, Attems J, Müller R, Gschwantler-Kaulich D, Manavi M, Huber I, Hoschützky H, Zielinski CC, Singer CF.
    Int J Cancer; 2006 Mar 01; 118(5):1126-34. PubMed ID: 16161043
    [Abstract] [Full Text] [Related]

  • 7. EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR.
    Gschwantler-Kaulich D, Hudelist G, Koestler WJ, Czerwenka K, Mueller R, Helmy S, Ruecklinger E, Kubista E, Singer CF.
    Oncol Rep; 2005 Aug 01; 14(2):305-11. PubMed ID: 16012707
    [Abstract] [Full Text] [Related]

  • 8. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA.
    Am J Ther; 2005 Aug 01; 12(3):243-53. PubMed ID: 15891269
    [Abstract] [Full Text] [Related]

  • 9. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M, Grell P, Simícková M, Fabian P, Petráková K, Palácová M, Macková D, Trojanec R, Hajdúch M, Pavlík T, Nenutil R, Vyzula R.
    Klin Onkol; 2008 Aug 01; 21(6):348-58. PubMed ID: 19382598
    [Abstract] [Full Text] [Related]

  • 10. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V, Witzel I, Lück HJ, Köhler G, von Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, Pantel K, Thomssen C.
    Breast Cancer Res Treat; 2004 Jul 01; 86(1):9-18. PubMed ID: 15218357
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V, Witzel I, Pantel K, Krenkel S, Lück HJ, Neumann R, Keller T, Dittmer J, Jänicke F, Thomssen C.
    Anticancer Res; 2006 Jul 01; 26(2B):1479-87. PubMed ID: 16619561
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ.
    Oncologist; 2006 Sep 01; 11(8):857-67. PubMed ID: 16951389
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE, Glass E, Blau R, Harman S.
    Breast Cancer Res Treat; 2009 Jan 01; 113(2):301-6. PubMed ID: 18273700
    [Abstract] [Full Text] [Related]

  • 16. [The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].
    Couto Mdo R, Pinto D, Oliveira J, Monteiro A, Pereira D, Medeiros R, Rodrigues H.
    Acta Med Port; 2011 Jan 01; 24(1):5-16. PubMed ID: 21672436
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
    Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4062-7. PubMed ID: 15217939
    [Abstract] [Full Text] [Related]

  • 19. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G, Colleoni M.
    Cancer; 2007 Aug 01; 110(3):509-17. PubMed ID: 17559147
    [Abstract] [Full Text] [Related]

  • 20. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
    Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, Borms M, Vindevoghel A, Jerusalem G, D'Hondt V, Dirix L, Canon JL, Richard V, Cocquyt V, Majois F, Reginster M, Demol J, Kains JP, Delree P, Keppens C, Sotiriou C, Piccart MJ, Cardoso F.
    Eur J Cancer; 2007 Mar 01; 43(4):725-35. PubMed ID: 17251007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.